Tuberculosis and viral hepatitis in patients treated with certolizumab pegol in Asia-Pacific countries and worldwide: real-world and clinical trial data

Grants

Funding Acknowledgements

UCB sponsored the clinical trials included in this analysis, as well as the analyses for this publication, and reviewed the text to ensure that from UCB perspective, the data presented in the publication are scientifically, technically, and medically supportable, that they do not contain any information that has the potential to damage the intellectual property of UCB, and that the publication complies with applicable laws, regulations, guidelines, and good industry practice.